The company doesn’t directly benefit from tariffs. Instead, the stock benefits from the disruptions tariffs are going to ...

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at ...

Research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Bradmer Pharmaceuticals in a note issued to investors on Monday, March 31st. Cantor Fitzgerald analyst B.

Two days after US President Donald Trump announced reciprocal tariffs on almost all countries, including American allies, ...

We recently published a list of 10 Firms Take a Beating on Tariff Worries. In this article, we are going to take a look at ...

National Bank Financial analyst John Shao, who has an “outperform” (similar to buy) and $22 on the stock, said the stock sell ...

Tether, by far the world’s largest stablecoin issuer, says it plans to create a new stablecoin for the U.S. market this year ...

Andres Sheppard of Cantor Fitzgerald reiterated a $15 price target on Rivian stock, despite underwhelming Q1 delivery and ...